A silicon body delivery system for targeting and activating CD44 molecules, its preparation method and use

Abstract

A silicon body delivery system for targeting activated CD44 molecules, a preparation method and use thereof, the surface of the silicon body is partially modified by a targeting ligand, and the targeting ligand is capable of interacting with the activated The ligand to which the CD44 molecule specifically binds. The silica body delivery system can be used for the diagnosis, prevention and treatment of vulnerable plaques or diseases related to vulnerable plaques.

Description

technical field [0001] The invention belongs to the technical field of targeted drug delivery, and in particular relates to a silicon body delivery system for targeting and activating CD44 molecules, especially vulnerable plaques. The present invention also relates to the preparation method and use of the silicon body delivery system, especially the use in the diagnosis, prevention and treatment of vulnerable plaques or diseases related to vulnerable plaques. Background technique [0002] At present, acute cardiovascular events, mainly acute myocardial infarction and sudden cardiac death, have become the number one killer of human health. According to statistics, about 20 million people die of acute cardiovascular events in the world every year. In China, the situation is also not optimistic. More than 700,000 people die of acute myocardial infarction and sudden cardiac death every year, which has become one of the most important diseases that seriously threaten the health ...

AI Technical Summary

Problems solved by technology

Therefore, the following problems will be encountered in the research and development of targeted drug delivery systems targeting CD44: if the affinity between CD44 and HA on the surface of target cells is not enough to provide significant specificity, then such targeted drug delivery systems will be difficult to obtain. There will be no specific targeting properties

[0012] So far, there is no report on the expression status of CD44 on the surface of macrophages, monocytes, endothelial cells, lymphocytes and smooth muscle cells mainly present in vulnerable plaques and its affinity for HA, nor does it exist. Any targeted drug delivery capable of stable and sustained release of drugs designed for the diagnosis or treatment of vulnerable plaques or diseases associated with vulnerable plaques using the interaction of HA and CD44 and the specific microenvironment of vulnerable plaques system prior art

Images